




FORM PTO-1449(Modified)	ATTY. DOCKET NO. N0260/7031		SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.		
	FILING DATE 03/09/99	GROUP 1612 1625	

LIST OF PATENTS AND
PUBLICATIONS FOR APPLICANT'S
INFORMATION DISCLOSURE
STATEMENT

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No	
BT	B1	0 693 498 A1	1/96	EPO	—	—		
BT	B2	0 615 752 A1	9/94	EPO	—	—		
BT	B3	0 599 576 A1	1/94	EPO	—	—		
BT	B4	0 030 009 A1	06/81	EPO	—	—		
BT	B5	2 698 269 A	08/05/97	France	—	—		
BT	B6	DE 422 4737	2/94	Schott, Herbert	—	—		
BT	B7	DE 2602175	07/29/76	Germany	—	—		
BT	B8	JP 9025231A	01/28/97	Japan	—	—	X	
BT	B9	JP 8027010A	01/30/96	Japan	—	—	X	
BT	B10	8163991A	06/25/96	Japan	—	—	X	
BT	B11	JP 75-9469	01/22/75	Japan	—	—		
BT	B12	JP 6016548A	01/25/94	Japan	—	—	X	
BT	B13	JP 1153629A	06/15/89	Japan	—	—	X	
BT	B14	1287022A	11/17/89	Japan	—	—	X	
BT	B15	JP 1203331A	08/16/89	Japan	—	—	X	
BT	B16	JP 9030963	2/97	Japan	—	—	X	
BT	B17	JP 815133	6/96	Japan	—	—	X	
BT	B18	JP 7082146	3/96	Japan	—	—	X	
BT	B19	JP 6072868	3/94	Japan	—	—	X	
BT	B20	59025327A	02/09/84	Japan	—	—	X	
BT	B21	JP 59-204175	11/84	Japan (English Abstract)	—	—		
BT	B22	JP 61204136	11/84	Japan (English Abstract)	—	—		
BT	B23	75-427/1983	4/83	Japan (English Abstract)	—	—	X	
BT	B24	ZA 9603433A	10/30/96	South Africa	—	—		
BT	B25	WO 98/17325	4/98	PCT	—	—		
BT	B26	WO 97/44336	11/27/97	PCT (7018 WO)	—	—		
BT	B27	WO 97/44063	11/27/97	PCT (7020 WO)	—	—		
BT	B28	WO 97/44026	11/27/97	PCT (7019 WO)	—	—		
BT	B29	WO 96/27380	09/96	PCT	—	—		
BT	B30	WO 96/12696	05/96	PCT	—	—		
BT	B31	WO 96/04001	2/1996	PCT	—	—		



FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. N0260/7031	SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.	
	FILING DATE 03/09/99	GROUP 1642/65

B32	WO 96/01259	1/1996	PCT				
B33	WO 95/33736	12/1995	PCT				
B34	WO 95/13271	5/1995	PCT				
B35	WO 95/13270	5/1995	PCT				
B36	WO 95/01969	1/1995	PCT				
B37	WO 94/24107	10/1994	PCT				
B38	WO 94/22887	10/1994	PCT				
B39	WO 94/13654	6/1994	PCT				
B40	WO 94/11547	5/1994	PCT				
B41	WO 94/07880	4/1994	PCT				
B42	WO 94/12530	6/1994	PCT				
B43	WO 92/20362	11/26/92	PCT (7007 WO)				
B44	WO 89/07938	9/89	PCT (7001 WO)				
B45	WO 85/00520	02/85	PCT				



FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPlicant. DOCKET NO. N0260/7031		SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.		
	FILING DATE 03/09/99	GROUP 1612/6-	

OTHER ART


(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

AT	C1	Anel, A., et al., "Increased Cytotoxicity Of Polyunsaturated Fatty Acids On Human Tumoral B And And T-Cell Lines Compared With Normal Lymphocytes", <i>Leukemia</i> , (1992), 6(7):680-688.
BT	C2	Anel, B., et al. "Cytotoxicity Of Chlorambucil And Chlorambucil-Fatty Acid Conjugates Against Human Lymphomas And Normal Human Peripheral Blood Lymphocytes", <i>Biochem Pharmacol</i> , (1990), 40(6):1193-1200.
BT	C3	Begin, M.E., et al., "Differential Killing Of Human Carcinoma Cells Supplemented With N-3 And N-6 Polyunsaturated Fatty Acids", <i>J Natl Cancer Inst</i> , (1986), 77(5):1053-1062. (Abstract)
BT	C4	Bourat, et al., "Long Chain Esters of Pipotiazine as Long-Acting Psychotropic Pro-Drug", <i>Med. Chem. Proc. Int. Symp.</i> 5th (1976) pp. 105-114.
BT	C5	Burns, C.P., et al., "Effect Of Docosahexaenoic Acid On Rate Of Differentiation Of HL-60 Human Leukemia", <i>Cancer Res</i> , (1989), 49:3252-3258.
BT	C6	Carboni et al., "Synthesis of a Photoaffinity Analog of Taxol as an Approach to Identify the Taxol Binding Site on Microtubules", <i>Journal of Medicinal Chem.</i> (8 September 1992).
BT	C7	Chajes, V., et al., "Influence Of N-3 Fatty Acids On The Growth Of Human Breast Cancer Cells In Vitro: Relationship To Peroxides And Vitamin-E", <i>Breast Cancer Res Treat</i> , (1995), 34:199-212.
BT	C8	de Antueno, R.J., et al., "In Vitro Effect Of Eicosapentaenoic And Docosahexaenoic Acids On Prostaglandin E2 Synthesis In A Human Lung Carcinoma", <i>Biochem Int</i> , (1989), 19(3):489-496. (Abstract)
BT	C9	de Smidt, P.C., et al., "Characteristics Of Association Of Oleoyl Derivatives Of 5-Fluorodeoxy-Uridine And Methotrexate With Low-Density Lipoproteins (Ldl)", <i>Pharm Res</i> , (1992), 9(4):565-569.
BT	C10	Deutsch, H.F., et al., "Cytotoxic Effects Of Daunomycin-Fatty Acid Complexes On Rat Hepatoma", <i>CELLS</i> , <i>Cancer Res</i> , (1983), 43:2668-2672.
BT	C11	Dhopeswarker, G., "Fatty Acid Transport Through the Blood-Brain Barrier.", <i>Biochim Biophys. Acta</i> 255:572-579, 1972.
BT	C12	D'Orlando, et al., "Citicoline (CDP-Choline): Mechanisms of Action and Effects in Ischemic Brain Injury", <i>Neurol. Res.</i> (1995) 17: 281-284 ,
BT	C13	Ehringer, W., et al., "A Comparison Of The Effects Of Linolenic (18:3 Omega 3) And Docosahexaenoic (22:6 Omega 3) Acids On Phospholipid Bilayers", <i>Chem Phys Lipids</i> , (1990), 54:79-88.
BT	C14	Falconer, J.S., et al., "Effect Of Eicosapentaenoic Acid And Other Fatty Acids On The Growth In Vitro Of Human Pancreatic Cancer Cell Lines", <i>Br. J. Cancer</i> , (1994,) 69:826-832.
BT	C15	Ferrari et al., "9-Cis-6,6'-Diapo-Gamma, Gamma-Carotenedioic Acid Derivatives And Pharmaceutical Compositions Containing Them", p. 710. Abs. 20423w, <i>Chem. Abs.</i> 95(23), 12/7/81, EP30,009 06/10/81 06/10/81 .
BT	C16	Georg et al., "The Medicinal Chemistry of Taxol", in "Taxol Science and Applications" ed. Matthew Suffness. Boca Raton: CRC Press, Inc., 1995, pp. 317-375.




FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. N0260/7031		SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.		
	FILING DATE 03/09/99		GROUP 1612

ST	C17	Guffy, M.M., et al., "Effect Of Cellular Fatty Acid Alteration On Adriamycin Sensitivity In Cultured L1210 Murine Leukemia Cells", <i>Cancer Res</i> , (1984), 44:1863-1866.
ST	C18	Hesse et al., "Inhibitory Effect of Cholesteryl- γ -Aminobutyrate" <i>Neurolpharmacology</i> , Vol. 24, No. 2, pp. 139-146 (1985) .
ST	C19	Hesse, et al., "Uptake in brain neurophysiological activity of two lipid esters of gamma-aminobutyric acid" <i>Neuropharmacol.</i> 27:6:637-40 (1988).
ST	C20	Higuchi et al., (Editors), Prodrugs as Novel Drug Delivery Systems, Acs Symposium Series, vol. 14, ACS, Washington, 1975, pp. 14-15.
ST	C21	Iwakami, et al., "Inhibition of Arochidonate 5-Lipoxygenase by Phenolic Compounds", <i>Chem. Pharm. Bull. (Japan)</i> , 34(9), 3960-3963 (1986)
ST	C22	Jacob, et al., "Synthesis, brain uptake and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor, gamma-vinyl-GABA," <i>J. Med. Chem.</i> 33:733-6 (1990).
ST	C23	Jacob, et al., γ -Aminobutyric Acid Esters.1. Synthesis...", <i>Journal of Medicinal Chemistry</i> , Vol. 28, No. 1, pp 106-110 (1985) .
ST	C24	Jacob, et al., γ -Aminobutyric Acid Esters.3. Synthesis, brain uptake and pharmacological properties of C-18 Glyceryl lipid esters of BAGA with varying degree of unsaturation," <i>J. Med. Chem.</i> 30:1573-6, 1987.
ST	C25	Jacobson, K., et al., Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors, <i>FEBS Letters</i> 225:1,2:97-102, (1987).
ST	C26	Jenski, L.J., et al., "Docosahexaenoic Acid-Induced Alteration Of Thy-1 And Cd8 Expression On Murine Splenocytes", <i>Biochim Biophys Acta</i> , (1995), 1236(1):39-50.
ST	C27	Jenski, L.J., et al., "Omega 3 Fatty Acids Increase Spontaneous Release Of Cytosolic Components From Tumor Cells", <i>Lipids</i> , (1991), 26(5):353-358.
ST	C28	Jenski, L.J., et al., "Omega-3 Fatty Acid-Containing Liposomes In Cancer Therapy", <i>Proc Soc Exp Biol Med</i> , (1995), 210(3):227-233.
ST	C29	Karmali, R.A., et al., "Effect Of Omega-3 Fatty Acids On Growth Of A Rat Mammary Tumor", <i>J Natl Cancer Inst</i> (1984), 73(2):457-461. (Abstract) .
ST	C30	Karmali, R., "N-3 Fatty Acids: Biochemical Actions In Cancer", <i>J. Nutr. Sci. Vitaminol. (Tokyo)</i> , (1992), 148-152. (Abstract) .
ST	C31	Kinsella, J.E., et al., "Effects Of Polyunsaturated Fatty Acids On The Efficacy Of Antineoplastic Agents Toward L5178y Lymphoma Cells", <i>Biochem Pharmacol</i> , (1993), 45(9):1881-1887. (Abstract),
ST	C32	Lohr, et al., "Neuroleptic-Induced Movement Disorders...", <i>Psychiatry</i> , Vol. 3, (1989).
ST	C33	Madhavi, N., et al., "Effect Of N-6 And N-3 Fatty Acids On The Survival Of Vincristine Sensitive And Resistant Human Cervical Carcinoma Cells In Vitro", <i>Cancer Lett</i> , (1994), 84:31-41.
ST	C34	Makino, et al., Chemical Abstracts, Vol. 106, No. 12, (90177x) issued 23 March 1987, "Pharmaceuticals Permeable to Blood-Brain Barrier".




FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. N0260/7031	SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.	
	FILING DATE 03/09/99	GROUP 1612/625

BT	C35	Mazumdar, et al., "Preparation and Evaluation of Ethambutol Derivatives", <i>Indian J. Pharm. Sci.</i> 47(6): 179-180 (1985) .
BT	C36	Minami, M., et al., "Effects Of Low-Dose Eicosapentaenoic Acid, Docosahexaenoic Acid And Dietary Fat On The Incidence, Growth And Cell Kinetics Of Mammary Carcinomas In Rats", <i>Oncology</i> , (1996), 53(5):398-405.
BT	C37	Nicolaou et al., "Design, Synthesis and Biological Activity of Protaxols", <i>Nature</i> , 364: 464-466 , (July 1993) 07/1993 .
BT	C38	Nishio, et al., "Novel Water-soluble Derivatives of Docosahexaenoic Acid Increase Diacyl-Glycerol Production Mediated by Phosphatidylcholine-Specific Phospholipase C", <i>Proc. Soc. Exp. Biol. Med.</i> (1993) 203(2):200-208.
BT	C39	Oshima, M., et al., "Effects Of Docosahexaenoic Acid (Dha) On Intestinal Polyp Development In Apc Delta 716 Apc Delta 716 Knockout Mice", <i>Carcinogenesis</i> , (1995), 16(11):2605-2607.
BT	C40	Pascale, A.W., et al., "Omega-3 fatty acid modification of membrane structure and function. Alteration by docosahexaenoic acid of tumor cell sensitivity to immune cytolysis", <i>Nutr Cancer</i> , (1993), 19(2):147-157.
BT	C41	Plumb, J.A., et al., "Effect Of Polyunsaturated Fatty Acids On The Drug Sensitivity Of Human Tumour Cell Lines Resistant To Either Cisplatin Or Doxorubicin", <i>Br J Cancer</i> , (1993), 67:728-733.
BT	C42	Rose, W.C., Preclinical Antitumor Activity of Taxanes", in "Taxol Science and Applications" ed. Matthew Suffness. Boca Raton: CRC Press, Inc., 1995, pp. 317-375.
BT	C43	Shashoua, et al., γ -Aminobutyric Acid Esters.1. Synthesis...", <i>J. of Med. Chem.</i> , Vol. 27, pp. 659-664 (1984) .
BT	C44	Shea, et al., <i>Developmental Brain Research</i> , 21:307-314 (1985).
BT	C45	Specter, R., "Fatty Acid Transport Through the Blood-Brain Barrier.", <i>J. of Neurochem.</i> , 50:2:639-643 (1988) .
BT	C46	Swindell, et al., "Characterization of the Taxol Structure-Activity Profile for the Locus of the A-Ring Side Chain Side Chain", <i>Bioorganic & Medicinal Chem. Ltrs.</i> , Vol.4, No. 12, pp. 1531-1536. (1994) .
BT	C47	Tessier, C., et al., "Docosahexaenoic Acid Is A Potent Inhibitor Of Rat Uterine Stromal Cell Proliferation", <i>Biochem Biophys Res Commun</i> , (1995), 207(3):1015-1021.
BT	C48	Tinsley, I.J., et al., "Influence Of Dietary Fatty Acids On The Incidence Of Mammary Tumors In The C3h Mouse", Ch3h Mouse", <i>Cancer Res</i> , (1981), 41:1460-1465.
BT	C49	Zerouga, M., et al., "Phospholipid Class As A Determinant In Docosahexaenoic Acid's Effect On Tumor Cell Viability", <i>Anticancer Res</i> , (1996), 16:2863-2868. (Abstract) .
BT	C50	Zijlstra, J.G., et al., "Influence Of Docosahexaenoic Acid In Vitro On Intracellular Adriamycin Concentration In Lymphocytes And Human Adriamycin-Sensitive And Resistant Small-Cell Lung Cancer Cell Lines, And On Cytotoxicity In The Tumor Cell Lines", <i>Int J Cancer</i> , (1987), 40:850-856.



FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. N0260/7031	SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.	
	FILING DATE 03/09/99	GROUP 1612 / 63


* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER 	DATE CONSIDERED 10.02
--	-----------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant

FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. N0260/7031	SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.	
	FILING DATE 03/09/99	GROUP 1612 <i>1625</i>




U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
<i>OP</i>	A1	5,994,392	11/30/99	Shashoua	514	437	
<i>DI</i>	A2	5,977,174	11/02/99	Bradley, et al.	514	549	
<i>M</i>	A3	5,955,459	09/21/99	Bradley, et al.	514	220	
<i>DI</i>	A4	5,925,669	07/1999	Katz, et al.	514	449	
<i>DI</i>	A5	5,919,815	07/06/99	Bradley, et al.	514	449	
<i>ST</i>	A6	5,827,819	10/27/98	Yatvin, et al.	514	2	
<i>DI</i>	A7	5,795,909	08/18/98	Shashoua, et al.	514	449	
<i>DI</i>	A8	5,750,572	05/12/98	Bruzzese	514	560	
<i>ST</i>	A9	5,654,290	08/05/97	Bayon, et al.	514	77	
<i>DI</i>	A10	5,604,216	02/18/97	Horrobin	514	182	
<i>DI</i>	A11	5,597,719	01/28/97	Freed, et al.	435	194	
<i>DI</i>	A12	5,580,899	12/03/96	Mayhew, et al.	514	449	
<i>DI</i>	A13	5,580,556	12/03/96	Horribin	424	85.4	
<i>DI</i>	A14	5,545,719	08/13/96	Shashoua	530	345	
<i>DI</i>	A15	5,516,800	05/14/96	Horrobin	514	560	
<i>DI</i>	A16	5,504,102 <i>ALL</i>	04/02/96	Agharkar, et al.	514	449	
<i>DI</i>	A17	5,484,876 <i>PMS</i>	2/94	Shashoua, et al.	514	549	
<i>DI</i>	A18	5,484,809	01/16/96	Hostetler, et al.	514	449	
<i>DI</i>	A19	5,476,954	12/19/95	Bourzat, et al.	549	510	
<i>DI</i>	A20	5,473,055	12/05/95	Mongelli, et al.	530	329	
<i>DI</i>	A21	5,468,754	11/21/95	Hausheer, et al.	514	283	
<i>DI</i>	A22	5,466,841	11/14/95	Horrobin, et al.	554	79	
<i>DI</i>	A23	5,453,521	09/26/95	Gaullier, et al.	549	541	
<i>DI</i>	A24	5,453,520	09/26/95	Bombardelli, et al.	549	510	
<i>DI</i>	A25	5,447,936	09/05/95	Hausheer, et al.	514	283	
<i>DI</i>	A26	5,411,947	05/02/95	Hostetler, et al.	514	43	
<i>DI</i>	A27	5,362,831	11/08/94	Mongelli, et al.	526	304	
<i>DI</i>	A28	5,356,928	10/18/94	Murray et al.	514	449	
<i>DI</i>	A29	5,336,684	08/09/94	Murray, et al.	514	449	
<i>DI</i>	A30	5,308,832	05/03/94	Garleb, et al.	514	2	
<i>DI</i>	A31	5,284,876	02/08/94	Shashoua	514	549	
<i>DI</i>	A32	5,276,020	1/94	Horribin, et al.	514	45	
<i>DI</i>	A33	5,250,722	10/05/93	Bombardelli, et al.	560	104	
	A34	5,246,726	09/21/93	Horrobin, et al.	424	646	



FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. N0260/7031		SERIAL NO. 09/265,307
	APPLICANT Nigel L. Webb et al.		
	FILING DATE 03/09/99		GROUP 1612 <i>1625</i>

<i>DT</i>	A35	5,223,263	06/29/93	Hostetler, et al.	424	450	
<i>DT</i>	A36	5,216,142	06/01/93	Horribin, et al.	514	50	
<i>DT</i>	A37	5,216,023	06/01/93	Literati-Nagy, et al.	514	538	
<i>DT</i>	A38	5,214,062	05/25/93	Mark, et al.	514	369	
<i>DT</i>	A39	5,194,654	03/16/93	Hostetler, et al.	558	152	
<i>DT</i>	A40	5,141,958	08/25/92	Crozier-Willi, et al.	514	558	
<i>DT</i>	A41	5,120,760	06/09/92	Horrobin	514	458	
<i>DT</i>	A42	5,116,624	05/26/92	Horrobin, et al.	424	702	
<i>DT</i>	A43	5,112,863	05/12/92	Hashimoto, et al.	514	534	
<i>DT</i>	A44	5,112,596	5/92	Malfroy-Camine	424	2	
<i>DT</i>	A45	4,968,672	11/06/90	Jacobson, et al.	514	46	
<i>DT</i>	A46	4,943,579	07/24/90	Vishnuvajjala, et al.	514	283	
<i>DT</i>	A47	4,939,174	07/03/90	Shashoua	514	549	
<i>DT</i>	A48	4,933,324	06/12/90	Shashoua	514	17	
<i>DT</i>	A49	4,902,505	2/90	Pardridge, et al.	424	85.7	
<i>DT</i>	A50	4,788,063	11/28/88	Fisher, et al.	424	449	
<i>DT</i>	A51	4,857,653	08/15/89	Colin, et al.	549	511	
<i>DT</i>	A52	4,814,470	03/21/98	Colin, et al.	514	449	
<i>DT</i>	A53	4,729,989	03/08/88	Alexander	514	192	
<i>DT</i>	A54	4,692,441	09/08/87	Alexander, et al.	514	194	
<i>DT</i>	A55	4,636,494	01/13/87	Growden, et al.	514	78	
<i>DT</i>	A56	4,550,109	10/29/85	Folkers, et al.	514	249	
<i>DT</i>	A57	4,088,646	05/09/78	Ishida, et al.	544	313	



TECH CENTER 1600 2002

RECEIVED

AUG 27 2002

FORM PTO-1449/6 and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.:	09/265,307	ATTY. DOCKET NO.	N0260/7031(KA/R)
				FILING DATE:	March 9, 1999		
				APPLICANT:	Webb, et al.		
				GROUP ART UNIT:	1625	EXAMINER:	B. T. ...
Sheet	1	of	2				

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		
BT		2001/0006962	A1	Myhren et al.	07-05-2001
BT		6,281,376		Whittaker et al.	08-28-2001
BT		6,245,811	B1	Horrobin et al.	06-12-2001
BT		6,166,089		Kozak	12-26-2000
BT		6,136,796		Kozak	10-24-2000
BT		6,077,837		Kozak	06-20-2000
BT		5,985,854		Kozak	11-16-1999

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
BT		WO	98/32718		PCT	07-30-1998	
BT		WO	96/34858		PCT	11-7-1996	
BT		WO	96/34855		PCT	11-7-1996	


OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
BT		ANSARI et al., "Fatty acid conjugates of xenobiotics," <i>Toxicol. Lett.</i> (1995), 75, 1-17.	
BT		Chen, et al. "Taxol Structure-Activity Relationships: Synthesis and Biological Evaluation of Taxol Analogs Modified at C-7," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 4, No. 18, pp. 2223-2228, 1994.	
BT		de Groot, et al., "Synthesis and Biological Evaluation of 2'-Carbamate-Linked and 2'-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin," <i>J. Med. Chem.</i> , 2000, Vol. 43, pp. 3093-3102.	
BT		DISCHINO et al., "Synthesis of the Monosodium Salt of Carbon-14 Labeled Paclitaxel (Taxol®) 2'-Ethyl Carbonate 7-Phosphonooxymethyl Ether, a Potential Prodrug of Paclitaxel", <i>J. of Labelled Compounds and Radiopharmaceuticals</i> , Vol. XXXIX, No. 2, 1997.	
BT		GREENWALD, et al., "Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates", <i>J. Org. Chem.</i> 1995, 60, pp. 331-336.	
BT		HALMOS et al., "Fatty acid conjugates of 2'-deoxy-5-fluorouridine as prodrugs for the selective delivery of 5-fluorouracil to tumor cells," <i>Biochem. Pharmacol.</i> (1992), 44(1), 149-155.	
BT		HONG et al., "Nucleoside-ether lipid conjugates as biotransformed prodrugs of antitumor and antiviral nucleosides," <i>J. Lipid Mediators Cell Signalling</i> (1994), 10, 159-161.	
BT		POUILLART "Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies," <i>Life Sci.</i> (1998), 63(20), 1739-1760.	
BT		UEDA, et al. "Synthesis and Antitumor Evaluation of 2'-Oxycarbonylpaclitaxels (Paclitaxel-2'-Carbonates)", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 4, No. 15, pp. 1861-1864, 1994.	



RECEIVED
AUG 27 2002
TECH CENTER 1600/2900

FORM P 1449a and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/265,307		ATTY. DOCKET NO.: N0260/7031(KA/RE)			
				FILING DATE: March 9, 1999					
				APPLICANT: Webb, et al.					
				GROUP ART UNIT: 1625		EXAMINER: B. Trinh			
Sheet	2	of	2						

EXAMINER 	DATE CONSIDERED 02-02
---	--------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.: 09/265,307

ATTY. DOCKET NO.:
N0260/7031(ERG)


FILING DATE: March 9, 1999

APPLICANT: Webb, et al.

GROUP ART UNIT: 1625

EXAMINER: B. Trinh

Sheet 1 of 1



RECEIVED
 FEB 28 2002
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		
ST	A1	5,059,699		Kingston, et al.	10-12-1991
ST	A2	5,278,324		Kingston et al.	01-11-1994
ST	A3	5,534,499		Ansell	07-09-1996
ST	A4	6,291,690		Mayhew et al.	09-18-2001

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)

EXAMINER

DATE CONSIDERED

2-1

12-02

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 08/135,291, filed August 17, 1998, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]